Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Cosentyx (secukinumab) Disease area(s): Immunology Manufacturer(s): Novartis 2024 Sales (USD): $6.14 billion Why it sold so well: In 2024, Novartis Cosentyx registered significant sales growth, with revenues increasing by 23% year-over-year to $6.14 billion
17: Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, Mast CJ, Stefanski A, Falcon B, Mojdami D
Individual providers may take a broader or narrower view within it, and a prescriber may still decline if the overall clinical picture does not support treatment
GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine
It is a dual GIP and GLP-1 receptor agonist, meaning it mimics two incretin hormones that help regulate insulin and glucose metabolism
US$ 25.34
US$ 24.86
US$ 28.82
